treatment
-
Alzheimer’s & Dementia Care
FDA Approves Auvelity as the First Non-Antipsychotic Treatment for Agitation Associated with Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel therapeutic option for the…
Read More » -
Alzheimer’s & Dementia Care
FDA designation may speed new treatment for Alzheimer’s psychosis
The U.S. Food and Drug Administration (FDA) has officially granted Fast Track designation to remlifanserin, an investigational therapeutic agent currently…
Read More » -
Alzheimer’s & Dementia Care
Patients can now skip infusions at hospital during early treatment for Alzheimer’s disease as the therapeutic landscape shifts toward at-home care.
In a landmark development for neurology and patient care, the U.S. Food and Drug Administration (FDA) has expanded the authorization…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval for Auvelity (dextromethorphan-bupropion) as a novel, first-in-class treatment specifically for…
Read More » -
Caregiver Support & Resources
Understanding and Addressing Pelvic Floor Dysfunction: A Comprehensive Guide to Symptoms, Risks, and Treatment
The often-jokingly dismissed inability to control bladder function during a cough, laugh, or sneeze is, in fact, a significant indicator…
Read More » -
Alzheimer’s & Dementia Care
FDA Reviews Expanded Approval for Subcutaneous Leqembi Iqlik, Offering At-Home Treatment from Initiation
The U.S. Food and Drug Administration (FDA) is currently reviewing a supplemental Biologics License Application (sBLA) submitted by Biogen and…
Read More » -
Alzheimer’s & Dementia Care
FDA Approves Auvelity, a First-in-Class Non-Antipsychotic Treatment for Agitation in Alzheimer’s Disease
The U.S. Food and Drug Administration (FDA) has granted approval to Auvelity (dextromethorphan-bupropion), marking a significant advancement in the management…
Read More » -
Alzheimer’s & Dementia Care
Study reports Alzheimer’s treatment gains in long-term care
Top-line data emanating from the BEACON study, a real-world observational investigation, indicate that Zunveyl (benzgalantamine) was linked to significant provider-reported…
Read More » -
Disability Support & Independent Living
FDA Withdraws Approval of Wellcovorin, GSK’s Branded Leucovorin, Amidst Complex History of Autism Treatment Claims
United States regulators have formally withdrawn the Food and Drug Administration’s (FDA) approval for Wellcovorin, the branded version of leucovorin…
Read More » -
Alzheimer’s & Dementia Care
Health Canada Conditionally Approves Leqembi, Marking a Pivotal Shift in Alzheimer’s Treatment by Targeting Underlying Disease Cause
Health Canada has granted conditional approval for Leqembi (lecanemab), a groundbreaking therapy co-developed by Eisai and Biogen, for specific adults…
Read More »
